Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alaunos Therapeutics, Inc.

Market Cap 5.47M 4.73M 4.36M 4.08M 7.66M 521M 7.77M 51.66M 20.07M 253M 20.54M 20.11M 877M P/E Ratio 2024
-0.65x
P/E Ratio 2025 -1.47x
Enterprise Value 4.09M 3.54M 3.26M 3.05M 5.72M 389M 5.81M 38.59M 14.99M 189M 15.35M 15.02M 655M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
85.97%
Yield 2024 *
-
Yield 2025 -
1 day+2.26%
1 week-7.38%
Current month-20.70%
1 month-14.07%
3 months-34.87%
6 months-47.07%
Current year-30.03%
1 week 1.92
Extreme 1.92
2.33
1 month 1.92
Extreme 1.92
3.09
Current year 1.92
Extreme 1.92
4.04
1 year 1.67
Extreme 1.67
6.2
3 years 1.31
Extreme 1.3137
79.59
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 2025-07-01
Director of Finance/CFO 41 2025-02-21
Director TitleAgeSince
Director/Board Member 57 2020-12-15
Chairman 63 2023-09-21
Director/Board Member 72 2021-02-04
Date Insider Type Main position Quantity % Market Cap.
05-21Free

Chief Executive Officer

3,700 0.1556%
04-28Free

Director

6,032 0.2703%
04-28Free

Director

6,515 0.2919%
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%-7.38%-26.62%-96.76% 5.35M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+1.06%-14.15%-17.13% 22.64B
+1.17%-6.74%-0.13%+394.19% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+1.22%+28.24%+176.72% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.73%-0.71%+23.29%+84.74% 20.99B
Weighted average by Cap. +1.58%+1.60%+33.63%+100.77%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.09 0.04 0.46 0.04 0.04 1.6 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.23 0.02 0.02 0.8
Net income -4.68M -4.05M -3.73M -3.49M -6.54M -445M -6.64M -44.15M -17.15M -216M -17.56M -17.19M -750M -4.18M -3.61M -3.33M -3.12M -5.84M -397M -5.93M -39.41M -15.31M -193M -15.67M -15.34M -669M
Net Debt -1.09M -943K -869K -814K -1.53M -104M -1.55M -10.3M -4M -50.47M -4.09M -4.01M -175M -1.38M -1.2M -1.1M -1.03M -1.94M -132M -1.97M -13.07M -5.08M -64.07M -5.2M -5.09M -222M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
26-06-12 2.260 $ +2.26% 7,291
26-06-11 2.210 $ +12.18% 20,979
26-06-10 1.970 $ -1.01% 12,373
26-06-09 1.990 $ -0.50% 27,095
26-06-08 2.000 $ -12.28% 31,799

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!